Business Context and Reporting Period
Company: SciSparc Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: May 2025 (Filing Date: May 13, 2025)
Principal Executive Offices: Tel Aviv, Israel
This filing reports a corporate development regarding a collaboration with Clearmind. On May 12, 2025, the Company issued a press release announcing the publication of a European Patent for a psychedelic-based combination therapy for cocaine addiction.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report of a specific event and does not contain financial statements or performance metrics.
Material Changes
Intellectual Property Milestone: The Company announced the publication of a European Patent in collaboration with Clearmind. The patent covers a psychedelic-based combination therapy specifically targeting cocaine addiction.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release detailing the patent publication but does not include forward-looking financial guidance, operational outlook, or specific risk factors within this document.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the scope and jurisdiction of the published European Patent for the cocaine addiction therapy.
- Review the terms of the collaboration agreement between SciSparc Ltd. and Clearmind.
- Check subsequent filings for any financial impact or commercialization timeline related to this patent.
- Confirm the status of the Company's cash position and runway, as this filing does not disclose liquidity data.